This is a modular phase I/IIa, multi-centre, multi-part, open-label, dose escalation, and dose expansion study.~Approximately 255 participants will be enrolled and assigned to study treatments.~This study consists of individual modules each evaluating safety and tolerability.~Core protocol which contains information applicable to all modules.~Module 1 (AZD9574 monotherapy):~Part A (dose-escalation cohorts) will include participants with advanced/relapsed ovarian, breast, pancreatic or prostate cancer that are deemed suitable for a Poly ADP-Ribose Polymerase (PARPi) by the Investigator.~Part B (dose-expansion cohorts):~Cohort B1 will include participants with advanced/relapsed Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer participants with BRCA mutated (BRCA1m, and BRCA2m), PALB2 mutation (PALB2m), RAD51Cm or RAD51Dm, without evidence of brain metastasis at baseline Magnetic Resonance Imaging (MRI) scan.~Cohort B2 will include participants with advanced/relapsed HER2-negative breast cancer participants with BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, who have either untreated or treated brain metastases that are not requiring immediate local therapy.~Module 2 (AZD9574 in combination with temozolomide (TMZ):~Part A (dose-escalation cohorts) will include participants with Isocitrate Dehydrogenase (IDH)-mutant glioma.~Dose expansion for Module 2 may be added in the future following a protocol amendment.
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed.